MedTrace Logo

A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test

NCT04529122 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2026-05-05

No results posted yet for this study

Summary

WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-27
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Argentina
  • Austria
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Egypt
  • Estonia
  • France
  • Germany
  • Greece
  • Hungary
  • India
  • Ireland
  • Israel
  • Lebanon
  • Mexico
  • Philippines
  • Poland
  • Portugal
  • Saudi Arabia
  • Serbia
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • United Arab Emirates
  • United Kingdom
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04529122 on ClinicalTrials.gov